KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin: 2010-2024

Historic EBT Margin for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -133.05%.

  • TherapeuticsMD's EBT Margin rose 11003.00% to 6.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year increase of 25161.00%. This contributed to the annual value of -133.05% for FY2024, which is 46157.00% up from last year.
  • Per TherapeuticsMD's latest filing, its EBT Margin stood at -133.05% for FY2024, which was up 77.62% from -594.62% recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's EBT Margin ranged from a high of 1.54% in FY2022 and a low of -3,082.20% during FY2021.
  • For the 3-year period, TherapeuticsMD's EBT Margin averaged around -242.05%, with its median value being -133.05% (2024).
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 279,930bps in 2021, then surged by 308,373bps in 2022.
  • Yearly analysis of 5 years shows TherapeuticsMD's EBT Margin stood at -282.90% in 2020, then plummeted by 279,930bps to -3,082.20% in 2021, then skyrocketed by 308,373bps to 1.54% in 2022, then tumbled by 59,616bps to -594.62% in 2023, then soared by 46,157bps to -133.05% in 2024.